Evidence map›Paper›PMID 27586016›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2016

The genotypic study of Mycobacterium tuberculosis complex resistant to isoniazid: Galicia, Spain (2008-2013).

M L Pérez Del Molino, G Barbeito-Castiñeiras, B Mejuto, P Alonso, A Fernández, G González-Mediero, Galician M. tuberculosis Resistance Group

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Prevalence ofJournal of clinical tuberculosis and other mycobacterial diseases · 2023
    Article
  2. Leprosy in the twenty-first century: a microbiological, clinical, and epidemiological study in northwestern Spain.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

M L Pérez Del MolinoMicrobiology Department, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
G Barbeito-CastiñeirasMicrobiology Department, Complexo Hospitalario Universitario de Santiago de Compostela-Universidade de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain. Gema.Barbeito.Castineiras@sergas.es.ORCID http://orcid.org/0000-0002-5889-9106
B MejutoPharmacology Department, Universidade de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
P AlonsoMicrobiology Department, Complexo Hospitalario Universitario de Lugo, Lugo, Spain.
A FernándezMicrobiology Department, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain.
G González-MedieroMicrobiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain.
Galician M. tuberculosis Resistance Group
Universidade de Santiago de Compostela · ESUniversity Hospital Complex Of Vigo · ESComplejo Hospitalario Universitario de Santiago · ESComplexo Hospitalario Universitario A Coruña · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incorporation of rapid detection systems to identify mutations in M. tuberculosis complex that confer resistance to isoniazid and rifampicin has potentiated the knowledge of their distribution, given the geographical variability. We performed antibiograms of the 2,993 strains isolated in Galicia, Spain (2008-2013). In the strains resistant to isoniazid, a concentration of 0.4 mg/mL and MTBDRplus Genotype test (Hain Lifescience, Germany) were used. We found that 3.64 % of strains were resistant to isoniazid, while 0.43 % were resistant to isoniazid and rifampicin (multidrug resistant, MDR). The MTBDRplus test showed an overall sensitivity of 72.48 %, with 62.5 % sensitivity for non MDR isoniazid-resistant strains and 100 % sensitivity for MDR strains. The katG gene mutation was detected at codon 315 in 38.53 % of strains. The S315T mutation appeared in 61.54 % of MDR strains and 34.38 % of non-MDR strains. The 28.44 % had mutations in inhA, (93.55 % in C15T), and 38.46 % of MDR strains were mutated. In non-MDR strains, 37.50 % were wild-type, 35.42 % and 27.08 % had mutations in katG and inhA, respectively. The most frequent mutation in rpoβ was S531L (46.15 %). The 38.71 % and 41.9 % of strains with resistance to isoniazid and streptomycin had mutations in katG and inhA, respectively (2 strains with mutations in T8C and T8A). The distribution pattern of resistance among strains with high and low concentrations of isoniazid showed statistically significant differences in relation to the mutation in katG and wild-type. The sensitivity of the Genotype MTBDRplus test for non-MDR strains in our area was at the lower threshold described.

Indexed as

Drug Resistance, BacterialGenotypeMutationAntitubercular AgentsGenotyping TechniquesHumansIsoniazidMicrobial Sensitivity TestsMycobacterium tuberculosisRetrospective StudiesRifampinSpainTuberculosisAntitubercular AgentsIsoniazidRifampin

Identifiers

PMID27586016
OpenAlexW2510488826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.